This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons

Sponsored by NOWDiagnostics, Inc.

About this trial

Last updated 4 years ago

Study ID

NOWDx COVID-19 Antibody OTC

Status

Terminated

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
2+ Years
All
All

Trial Timing

Ended 4 years ago

What is this trial about?

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

What are the participation requirements?

Yes

Inclusion Criteria

- PCR positives: persons who were symptomatic for COVID-19 and have tested positive for COVID-19 with an EUA or FDA cleared PCR test; 7+ days post positive PCR test

- PCR negatives: persons who have never had COVID-19 and who have tested negative for COVID-19 with an EUA or FDA cleared PCR test; within 0-6 days post negative PCR test

- persons 2+ years old Vaccination Cohort>

- persons 7- 60 days post second dose of EUA COVID-19 vaccine

- persons 18+ years old

No

Exclusion Criteria

- PCR positives: persons with a COVID-19 positive test result >45 days old

- PCR negatives: persons with any prior COVID-19 positive result

- persons who have received COVID-19 vaccine

- persons <2 years old Vaccination Cohort>

- persons symptomatic or previously infected with COVID-19 prior to vaccination

- persons <18 years old

Locations

Location

Status